Alios BioPharma and Versitech partner for influenza therapy

admin

Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.

Free Report

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:

Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.

Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.

Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza virus.

Free Report

How is the Biopharmaceutical industry evolving?

Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

By GlobalData